Market capitalization | $5.03b |
Enterprise Value | $3.45b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 341.05 |
P/S ratio (TTM) P/S ratio | 497.28 |
P/B ratio (TTM) P/B ratio | 3.34 |
Revenue growth (TTM) Revenue growth | -0.19% |
Revenue (TTM) Revenue | $10.12m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
11 Analysts have issued a Avidity Biosciences Inc forecast:
11 Analysts have issued a Avidity Biosciences Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 10 10 |
0%
0%
|
|
Gross Profit | 7.46 7.46 |
22%
22%
|
|
EBITDA | -322 -322 |
48%
48%
|
EBIT (Operating Income) EBIT | -325 -325 |
46%
46%
|
Net Profit | -280 -280 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) designed to treat a range of serious diseases. The company's lead product candidate is AOC 1001 for treatment of myotonic dystrophy type 1; and four other muscle programs, which focus on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. It utilizes its proprietary AOC platform to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. The company also has development programs that focuses on immune and other cell types. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.
Head office | United States |
CEO | Sarah Boyce |
Employees | 253 |
Founded | 2012 |
Website | www.aviditybiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.